Recently, HealthCare Executive, an authoritative media in the pharmaceutical industry, released the rankings of 2022 Top 100 Chinese Pharmaceutical Innovative Companies and China's 50 Pharmaceutical Innovation and Upgrading Role Models. Hansoh Pharma was ranked in the first echelon of China's Top 100 Innovative Pharmaceutical Companies for the fourth consecutive year and among the top 5 out of China's 50 Pharmaceutical Innovation and Upgrading Role Models.
Considering the reality of pharmaceutical innovation, HealthCare Executive selected Top 100 Chinese Pharmaceutical Innovative Companies representing the innovation strength of China's pharmaceutical industry based on four indicators: the number of granted patents, the total number of patent citations, the number of clinical trials, and the number of approved and marketed innovative drugs. Hansoh Pharma has been selected and maintained in the first echelon for four consecutive years. Released for the first time this year, the ranking of China's 50 Pharmaceutical Innovation and Upgrading Role Models screened out companies that played an exemplary role in the innovation and upgrading of product lines and corporate strategies based on three indicators: revenue, net profit and R&D investment. Hansoh Pharma's ranking among the top 5 reflects its strength and position in the field of pharmaceutical innovation and demonstrates the full recognition of its innovation strength by industry authorities.
As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma has taken innovation and R&D as its core development strategy since its inception. With four R&D centers in Maryland of the U.S. and Shanghai, Lianyungang and Changzhou of China, Hansoh Pharma focuses on the treatment of major diseases such as oncology, CNS diseases, anti-infectives and diabetes, stands at the forefront of global pharmaceutical innovation, and builds a comprehensive innovation platform covering technology innovation, product innovation and industry innovation. After years of continuous high-intensity R&D investment, Hansoh Pharma has entered the harvest period of R&D achievements. Up to now, it has successfully marketed six innovative drugs, and is conducting 40+ clinical trials on 25+ innovative drug projects at different clinical stages; successfully commercialized innovative drugs have become its main growth engine. Hansoh Pharma has been ranked among the world's Top 100 Pharmaceutical Companies and China's Top Three Best Industrial Enterprises in Pharmaceutical R&D Pipeline for many consecutive years.
Driven by the dual-engine strategy of "independent development & BD", Hansoh Pharma is intensifying efforts to establish global presence in frontier new drug fields. In the first half of this year, Hansoh Pharma has taken a bold move towards siRNA and ADC, made a rapid start in anti-coronavirus oral drug cooperation, and achieved milestones in several license-in/out projects. Based on its internationally leading new drug technology platform, Hansoh Pharma has stepped into the biopharmaceutical arena and extended its R&D coverage to monoclonal antibody, double antibody, ADC, fusion protein, etc. While the platform for independent innovation and global cooperative innovation has become more dynamic, the global innovation ecosystem has taken initial shape. In recent years, Hansoh Pharma has been accelerating the commercialization of its independent innovation results, and by the first half of 2022, the revenue share of innovative drugs has exceeded 50%, successfully transforming it into an innovative pharmaceutical company featuring innovation-driven growth.
Innovation leads development and technology shapes a better future. Hansoh Pharma will further deepen the innovation-driven strategy and leverage the global innovation ecosystem towards its goal to meet urgent clinical needs, and on the basis explore and develop more innovative and good drugs for improved health and quality of life of human beings.
